New CAR-T therapy targets tough childhood cancers

NCT ID NCT06508931

Recruiting now Disease control Sponsor: Miltenyi Biomedicine GmbH Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a new type of CAR-T cell therapy called MB-CART2019.1 in children and teens (ages 6 months to under 18) with B-cell cancers that have come back or not responded to standard treatments. The therapy uses the patient's own immune cells, modified to attack cancer cells carrying two markers (CD20 and CD19). The study aims to see how well it shrinks tumors and to monitor side effects. About 31 participants will be enrolled across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zamtocabtagene autoleucel (MB-CART2019.1), a type of CAR-T cell therapy that targets two proteins (CD20 and CD19) on cancer cells
What this could lead to: If this works, it could offer a new treatment option for children with aggressive B-cell cancers that have not responded to other therapies.
What could go wrong: This is a small, early-phase trial with only 31 participants, so results may not apply to everyone. CAR-T therapy can cause serious side effects like cytokine release syndrome or neurological problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGGRESSIVE MATURE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aggressive B-cell non-Hodgkin lymphoma B-cell neoplasm Burkitt lymphoma diffuse large B-cell lymphoma primary mediastinal large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL NEOPLASM

Contacts and locations

Locations

Hôpital Robert Debré
ACTIVE_NOT_RECRUITING

Paris, Boulevard Sérurier 48, 75019, France
IRCCS Ospedale Pediatrico Bambino Gesù
RECRUITING

Rome, Piazza Sant Onofrio 4, 00165, Italy
Institut Gustave Roussy
RECRUITING

Villejuif, 94805, France
Prinses Maxima Centrum
ACTIVE_NOT_RECRUITING

Utrecht, Heidelberglaan 25, Netherlands
Universitaetsklinikum Muenster (UKM) - Klinik fuer Kinder- und Jugendmedizin - Paediatrische Haematologie und Onkologie
ACTIVE_NOT_RECRUITING

Münster, Albert-Schweitzer-Campus 1, Gebaeude A1, 48129, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.